Want to see PBIO full AI Analyst Report?
PBIO Stock Chart & Stats
$0.10
<$0.01(30.00%)
At close: 4:00 PM EST
$0.10
<$0.01(30.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.10
Previous CloseN/A
Volume28.50K
Average Volume (3M)1.17K
Market Cap
$16.39K
Enterprise Value$22.85M
Total Cash (Recent Filing)$14.25K
Total Debt (Recent Filing)$29.19M
Price to Earnings (P/E)―
Beta34.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,967,083
10 Day Avg. Volume345
30 Day Avg. Volume1,173
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.24
Price to Sales (P/S)3.89
P/FCF Ratio-2.41
Enterprise Value/Market Cap1.39K
Enterprise Value/Revenue15.27
Enterprise Value/Gross Profit-252.74
Enterprise Value/Ebitda-2.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Innovative TechnologyThe unique PCT technology provides a competitive edge in enhancing scientific research efficiency, supporting long-term growth in biotech and pharma sectors.
Diverse Revenue StreamsDiverse revenue streams from instruments, consumables, and services offer stability and potential for growth across multiple sectors.
Market Expansion PotentialExpanding applications of PCT technology across sectors can increase market penetration and customer base, driving long-term revenue growth.
Bears Say
Financial InstabilityPersistent financial instability with high leverage and negative cash flows threatens long-term viability and limits investment in growth initiatives.
Negative Cash FlowNegative cash flow indicates reliance on external financing, which may not be sustainable, affecting the company's ability to fund operations and growth.
High Debt LevelsHigh debt levels can strain financial resources, increasing risk and limiting flexibility to invest in strategic opportunities.
Pressure Biosciences News
PBIO FAQ
What was Pressure Biosciences’s price range in the past 12 months?
Pressure Biosciences lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
What is Pressure Biosciences’s market cap?
Pressure Biosciences’s market cap is $16.39K.
When is Pressure Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pressure Biosciences’s earnings last quarter?
Currently, no data Available
Is Pressure Biosciences overvalued?
According to Wall Street analysts Pressure Biosciences’s price is currently Overvalued.
Does Pressure Biosciences pay dividends?
Pressure Biosciences does not currently pay dividends.
What is Pressure Biosciences’s EPS estimate?
Pressure Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pressure Biosciences have?
Pressure Biosciences has 40,967,083 shares outstanding.
What happened to Pressure Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pressure Biosciences?
Currently, no hedge funds are holding shares in PBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pressure Biosciences
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company’s products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB440, Barocycler HUB880, and the Shredder SG3; Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle; UltraShear Mini, UltraShear K45, and UltraShear Max; and application specific kits, as well as consumable products. The company also provides pain relief, skincare solutions, personal wellness, athletic recovery, and specialized pet care products. It serves researchers at academic laboratories, government agencies, biotechnology and pharmaceutical companies, other life science institutions, and food/beverages laboratories. The company has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. Pressure BioSciences, Inc. was incorporated in 1978 and is headquartered in Canton, Massachusetts.
Technical Analysis
Nuwellis
―
Aethlon Medical
―
Bone Biologics
―
Bluejay Diagnostics
―
DIH Holdings US, Inc Class A
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors